5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study
作者:Tran Huong、Do Dung、Dao Oanh、Tran Lan、Phan Dung、Vu Duc Loi、Kyung Kim、Byung Han、Jieun Yun、Jong Kang、Youngsoo Kim、Sang-Bae Han、Nguyen-Hai Nam
DOI:10.2174/1573406410666140925153128
日期:2015.3.31
The search for newer histone deacetylase (HDAC) inhibitors has attracted a great deal of
interest of medicinal chemists worldwide, especially after the first HDAC inhibitor (Zolinza®, widely
known as SAHA or Suberoylanilide hydroxamic acid) was approved by the FDA for the treatment of Tcell
lymphoma in 2006. As a continuity of our ongoing research in this area, we designed and synthesized
a series of 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as analogues of SAHA and evaluated their
biological activities. Most of the compounds in this series, e.g. compounds with 5-aryl moiety being 2-
furfuryl (5a), 5-bromofuran-2-yl (5b), 5-methylfuran-2-yl (5c), thiophen-2-yl (5d), 5-methylthiophen-2-yl
(5f) and pyridyl (5g-i), were found to have potent anticancer cytotoxicity with IC50 values of generally 5-
to 10-fold lower than that of SAHA in 4 human cancer cell lines assayed. Those compounds with potent
cytotoxicity were also found to have strong HDAC inhibition effects. Docking studies revealed that
compounds 5a and 5d displayed high affinities towards HDAC2 and 8.
对新型组蛋白去乙酰化酶(HDAC)抑制剂的研究引起了全球药物化学家的极大兴趣,尤其是在2006年首个HDAC抑制剂(Zolinza®,广泛称为SAHA或亚油酰苯胺羟肟酸)获得FDA批准用于治疗T细胞淋巴瘤之后。作为我们在该领域持续研究的延续,我们设计并合成了一系列基于5-芳基-1,3,4-噻二唑的羟肟酸,作为SAHA的类似物并评估其生物活性。在这一系列化合物中,大多数,如5-芳基取代基为2-呋喃基(5a)、5-溴呋喃-2-基(5b)、5-甲基呋喃-2-基(5c)、噻吩-2-基(5d)、5-甲基噻吩-2-基(5f)和吡啶基(5g-i)的化合物,发现具有强效的抗癌细胞毒性,其IC50值通常比SAHA在4种人类癌细胞系中的值低5到10倍。这些具有强效细胞毒性的化合物也被发现具有显著的HDAC抑制作用。对接研究表明,化合物5a和5d对HDAC2和HDAC8表现出高亲和力。